Phase 4 N=17 Bronchodilator Responsiveness in Obliterative Bronchiolitis
Obliterative Bronchiolitis
Primary: Per Cent Change of Forced Expiratory Volume in 1 Second (FEV1) After Bronchodilators — 14; 7 per cent positive change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=55 Progression of Airway Obstruction in Childhood Asthma
Asthma
Primary: Airway Wall Thickness — 1.5; 1.5; 1.4; 1.6 mm — p=0.2
Phase 4 N=60 Efficacy of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Children (5-<12 Years) With Acute Bronchial Obstruction
Acute Bronchial Obstruction, Asthma
Primary: Mean Change in Maximum Expiratory Flow From Baseline to Final Evaluation — 44; 43.67 Liters/minute
Phase 2 N=31 Efficacy (Bronchoprotection) and Safety of Orally Inhaled BI 1744 CL in Patients With Intermittent Asthma
Asthma
Primary: Adjusted Mean of Provocative Concentration of Methacholine Required to Produce a 20% Decrease in FEV1 (PC20FEV1) at 24 Hours — 0.793; 1.950; 2.504; 3.236 Log base 2…
Phase 2 N=18 PEEP as Rescue Therapy for Asthmatics With Elevated BMI
Asthma
Primary: Central and Peripheral Elastance — 391; 461; 587; 334 cmH2O/L
N/A N=25 Neurostimulation for the Relief of Acute Bronchoconstriction
Asthma
Primary: Safety- Number of Participants With Adverse Events — 16 Participants
N/A N=30 Relief of Acute Bronchoconstriction/Asthma Using the Non-Invasive AlphaCore Device
Asthma
Primary: Safety- Number of Participants With Adverse Events — 10 Participants
N/A N=21 Positive Airway Pressure for the Treatment of Asthma
Asthma · Sleep Apnea
Primary: Asthma Control Test — 19.3; 19.8; 19.1; 19.6 units on a scale — p=0.8
N/A N=141 A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation
Asthma
Primary: Number of Participants With Bronchodilation — 74; 67 Participants
Phase 2 N=8 A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)
Atopic Asthma
Primary: Number of Subjects With Serious Adverse Events — 0; 0 participants
Phase 4 N=52 Positive Expiratory Pressure for the Treatment of Acute Asthma in Children
Asthma
Primary: Change in Pulmonary Asthma Score (PAS) — 0.9; 0.4 mean PAS score
N/A N=31 Effectiveness of the Aeroneb in Acute Severe Asthma
Asthma Exacerbation
Primary: Percentage Change in Mean of Peak Expiratory Flow Rate (PEFR) Percentage of Predicted Baseline at 30 Minutes After the Initial Bronchodilator Treatment — 18.1; 12.9…
N/A N=16 Optimal Albuterol Regimens for Acute Asthma Exacerbations: DBRCT Pilot Study
Acute Asthma
Primary: %FEV1 — 20; 34; 26; 31 %-predicted
N/A N=22 Acute Effect of Mometasone on Beta-adrenergic Airway and Airway Vascular Relaxation in Severe Asthma
Asthma
Primary: Albuterol-induced Change in FEV1 — 0.27; 0.18; 0.32; 0.20 liters
Phase 2 N=15 PF-04191834 Single Dose Bronchodilatory Study In Asthma.
Asthma
Primary: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) — 2.624; 2.626; 2.585; 2.579 L
Phase 2 N=66 Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients
Exercise Induced Asthma
Primary: Percent Change in Maximum Post-exercise Forced Expiratory Volume in One Second (FEV1) Fall After 6 Weeks — -5.85; 0.61; -5.24 Percent change
Phase 3 N=17 PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction
Asthma
Primary: Part 1: Change From Mannitol Baseline Forced Expiratory Volume in the First Second (FEV1) Area Under the Curve (AUC [0-60 Min]) Post-mannitol Challenge 1…
Phase 3 N=225 MK0476 Study in Adult Patients With Acute Asthma (0476-322)
Asthma
Primary: The Time-weighted Average of Change in Forced Expiratory Volume in One Second (FEV1) — 0.09; 0.17; 0.01 Liter — p=0.022
Phase 1 N=37 BI 443651 Methacholine Challenge
Asthma
Primary: Absolute Change From Baseline in Maximum Forced Expiratory Volume Within 1 Second (FEV1) Reduction Following Bolus Methacholine Challenge in Part 1 — 0.018; 0.390…
N/A N=284 Bronchial Thermoplasty in Severe Persistent Asthma
Severe Asthma
Primary: Subjects Experiencing Severe Exacerbations (Rates) — 132; 118; 118; 106 Participants
Phase 4 N=10 Aerosolized Beta-Agonist Isomers in Asthma
Asthma
Primary: Change in Maximum Forced Expiratory Volume at One Second (FEV1) — 20; 20; 20; 19 percentage of change
Phase 4 N=62 Hypertonic Saline for Acute Bronchiolitis
Bronchiolitis, Viral · Saline Solution, Hypertonic
Primary: Respiratory Assessment Change Score (RACS) — -1.5; -4 units on a scale — p=0.01
Phase 4 N=18 Salbutamol Use in Ozone Air Pollution by People With Asthma and/or Exercise Induced Bronchoconstriction (EIB)
Asthma and/or Exercise Induced Bronchoconstriction · Ozone Air Pollution
Primary: Measured Before and 30 Minutes After Exercise in Each 1 Day Condition — 6.98; 5.96; -1.38; -.35 litres
N/A N=14 Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway
Asthma
Primary: Maximum Change From Baseline in Airway Blood Flow (Qaw) — -11.0; 14.1; 23.9; 25.5 change from baseline ( µl/min/ml) — p=< 0.001
N/A N=7 Imaging Study of the Lungs During an Allergic Asthma Attack
Asthma · Atopy
Primary: Percentage Change in the Ratio of Mean-normalized Perfusion Within Ventilation Defective Regions Relative to Outside — -17.8 percentage
N/A N=222 Asthma Express: Bridging the Emergency to Primary Care in Underserved Children
Asthma
Primary: Symptom Days — 6.24; 4.82 symptom days over past 14 days — p=0.06
Phase 3 N=945 The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room
Status Asthmaticus
Primary: Patients Hospitalization Rate — 82; 75 participants
Phase 4 N=179 Budesonide Inhalation Suspension for Acute Asthma in Children
Asthma · Acute Asthma · Reactive Airway Exacerbation
Primary: Median Change in Asthma Score 2 Hours After Intervention — -3; -3 Units on a scale — p=0.44
Phase 3 N=60 Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3
Asthma
Primary: Provocative Concentration of Methacholine Which Produces a 20% Fall in FEV1 (PC20) — 17.70; 9.88; 20.10; 10.78 mg/mL — p=<0.001
Phase 4 N=49 Intramuscular Epinephrine as an Adjunctive Treatment for Severe Pediatric Asthma Exacerbation
Asthma
Primary: Change in Percent of Predicted Peak Expiratory Flow Rate (PEFR) at t15 — 59.56; 52.45 percentage of predicted